{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:13:29Z","timestamp":1790266409781,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Generalized Anxiety Disorder (GAD) is a mental health condition with a recent increase in prevalence. GAD is often underdiagnosed, leading to negative consequences for individuals, healthcare systems, and society. The economic burden and impaired quality of life associated with GAD underscores the need for effective treatment. Pregabalin has shown promise in reducing anxiety symptoms; however, further research is needed to evaluate its efficacy and compare it with other treatment options. This study aimed to assess the efficacy, safety, and optimal pregabalin dosage for the treatment of GAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This meta-analysis followed PRISMA guidelines. Pregabalin-treated patients comprised the intervention group, whereas the comparator group received benzodiazepines, SSRIs, SNRIs, or placebo. Efficacy and safety were evaluated using various scales and adverse events (AEs). Randomized clinical trials were included in the study. Four major databases were used for this study. Outcome measures included the Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression Improvement Scale (CGI-I), discontinuation rates, costs, and quality-adjusted life-years (QALYs). Meta-analyses were conducted using Review Manager 5.4 software, employing odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs). Subgroup and sensitivity analyses were performed based on follow-up and dosage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen studies involving 4,822 patients were analyzed. Pregabalin demonstrated superior efficacy in reducing HAM-A global scores at 2\u00a0weeks (MD \u22121.23, 95% CI \u22121.79 to \u22120.66), 4\u00a0weeks (MD \u22121.12, 95% CI \u22121.60 to \u22120.63), 8\u00a0weeks (MD \u22122.50, 95% CI \u22124.21 to \u22120.79), 12\u00a0weeks (MD 0.99, 95% CI 0.35\u20131.63), and 6\u00a0months to 1\u00a0year (MD \u22123.31, 95% CI \u22124.30 to \u22122.31). Pregabalin also showed a higher response rate to HAM-A (OR 1.51, 95% CI 1.31 1.75). CGI-I scores favored pregabalin (MD \u22120.25, 95% CI \u22120.38 to \u22120.12), with a higher response rate (OR 1.33, 95% CI 1.15\u20131.55). The discontinuation rates were lower with pregabalin (OR 0.80, 95% CI 0.70, 0.91). Adverse events favored pregabalin over SSRIs\/SNRIs and benzodiazepines at different doses. Pregabalin was associated with higher cost-effectiveness (MD 0.02, 95% CI 0.01, 0.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pregabalin is an effective and well-tolerated treatment for generalized anxiety disorder, showing superior efficacy and safety compared with first-line medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42024556152.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1483770","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T04:05:00Z","timestamp":1738901100000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness"],"prefix":"10.3389","volume":"16","author":[{"given":"Narcis","family":"Cardoner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Guti\u00e9rrez-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Lahera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"\u00c1lvarez-Mon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pino","family":"Alonso Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"P\u00e9rez-P\u00e1ramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fncel.2020.00083","article-title":"Pregabalin as a pain therapeutic: beyond calcium channels","volume":"14","author":"Alles","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12991-014-0040-0","article-title":"Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors","volume":"14","author":"\u00c1lvarez","year":"2015","journal-title":"Ann. general psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2147\/JMDH.S280200","article-title":"Economic and humanistic burden associated with depression and anxiety among adults with non-communicable chronic diseases (NCCDs) in the United States","volume":"14","author":"Armbrecht","year":"2021","journal-title":"J. Multidiscip. Healthc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3899\/jrheum.141196","article-title":"Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: a randomized, placebo-controlled study","volume":"42","author":"Arnold","year":"2015","journal-title":"J. rheumatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.clinthera.2009.06.004","article-title":"Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder","volume":"31","author":"Bereza","year":"2009","journal-title":"Clin. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? A systematic review","volume":"27","author":"Bonnet","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1177\/070674371105600907","article-title":"A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder","volume":"56","author":"Boschen","year":"2011","journal-title":"Rev. Can. Psychiatr."},{"key":"B8","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry Edgmont Pa, Townsh."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","year":"2021","journal-title":"Lancet London, Engl."},{"key":"B10","first-page":"2120","article-title":"Pregabalin versus sertraline in generalized anxiety disorder. An open label study","volume":"19","author":"Cvjetkovic-Bosnjak","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"ITC49","DOI":"10.7326\/AITC201904020","article-title":"Generalized anxiety disorder","volume":"170","author":"DeMartini","year":"2019","journal-title":"Ann. Intern. medicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/YIC.0b013e3282f0f0d7","article-title":"Long-term efficacy of pregabalin in generalized anxiety disorder","volume":"23","author":"Feltner","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/01.jcp.0000084032.22282.ff","article-title":"A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder","volume":"23","author":"Feltner","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/YIC.0b013e32834519bd","article-title":"Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study","volume":"26","author":"Feltner","year":"2011","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/YIC.0000000000000147","article-title":"Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis","volume":"32","author":"Generoso","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/YIC.0b013e3283491fd5","article-title":"Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study","volume":"26","author":"Greist","year":"2011","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/0269881111405360","article-title":"Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial","volume":"26","author":"Hadley","year":"2012","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"B19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-244X-14-128","article-title":"The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review","volume":"14","author":"Haller","year":"2014","journal-title":"BMC psychiatry"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1007\/s11695-022-06109-6","article-title":"Analgesic efficacy of gabapentin and pregabalin in patients undergoing laparoscopic bariatric surgeries: a systematic review and meta-analysis","volume":"32","author":"Hung","year":"2022","journal-title":"Obes. Surg."},{"key":"B22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/gps.3800","article-title":"Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study","volume":"28","author":"Karaiskos","year":"2013","journal-title":"Int. J. geriatric psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/yic.0b013e32831d7980","article-title":"Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial","volume":"24","author":"Kasper","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1017\/S1461145713001557","article-title":"Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder","volume":"17","author":"Kasper","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"580858","DOI":"10.3389\/fphar.2020.580858","article-title":"Comparative remission rates and tolerability of drugs for generalised anxiety disorder: a systematic review and network meta-analysis of double-blind randomized controlled trials","volume":"11","author":"Kong","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1192\/bjp.bp.107.037788","article-title":"Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder","volume":"193","author":"Montgomery","year":"2008","journal-title":"Br. J. psychiatry J. Ment. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.4088\/jcp.v67n0511","article-title":"Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine","volume":"67","author":"Montgomery","year":"2006","journal-title":"J. Clin. psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1177\/0269881108094722","article-title":"Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model","volume":"23","author":"Nutt","year":"2009","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"B29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/YIC.0000000000000087","article-title":"Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms","volume":"30","author":"Olivares","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e023600","DOI":"10.1136\/bmjopen-2018-023600","article-title":"Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials","volume":"9","author":"Onakpoya","year":"2019","journal-title":"BMJ open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ Clin. Res. ed."},{"key":"B32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: a placebo-controlled trial","volume":"160","author":"Pande","year":"2003","journal-title":"Am. J. psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jclinepi.2003.05.001","article-title":"Prescription psychotropic medication use among the U.S. adult population: results from the third National Health and Nutrition Examination Survey, 1988-1994","volume":"57","author":"Paulose-Ram","year":"2004","journal-title":"J. Clin. Epidemiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jpsychires.2023.06.009","article-title":"The comorbidity between borderline personality disorder (BPD) and generalized anxiety disorder (GAD): a systematic review and meta-analysis","volume":"164","author":"Qadeer Shah","year":"2023","journal-title":"J. psychiatric Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jad.2011.11.014","article-title":"Humanistic and economic burden of generalized anxiety disorder in North America and Europe","volume":"140","author":"Revicki","year":"2012","journal-title":"J. Affect. Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","article-title":"Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam","volume":"62","author":"Rickels","year":"2005","journal-title":"Archives general psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/YIC.0b013e328350b133","article-title":"Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment","volume":"27","author":"Rickels","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/01.nmd.0000198140.02154.32","article-title":"Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients","volume":"194","author":"Rodriguez","year":"2006","journal-title":"J. Nerv. Ment. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.schres.2017.09.014","article-title":"Pregabalin for anxiety in patients with schizophrenia - a randomized, double-blind placebo-controlled study","volume":"195","author":"Schjerning","year":"2018","journal-title":"Schizophrenia Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jad.2012.10.031","article-title":"Recurrence of anxiety disorders and its predictors","volume":"147","author":"Scholten","year":"2013","journal-title":"J. Affect. Disord."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1186\/s12889-023-16051-6","article-title":"Misuse of Pregabalin: a qualitative study from a patient's perspective","volume":"23","author":"Servais","year":"2023","journal-title":"BMC Public Health"},{"key":"B42","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1478-7547-11-8","article-title":"A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal","volume":"11","author":"Silva Miguel","year":"2013","journal-title":"Cost Eff. Resour. allocation C\/E"},{"key":"B44","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/occmed\/kqv054","article-title":"Hamilton rating scale for anxiety (HAM-A)","volume":"65","author":"Thompson","year":"2015","journal-title":"Occup. medicine Oxf. Engl."},{"key":"B45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10198-009-0160-7","article-title":"Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective","volume":"11","author":"Vera-Llonch","year":"2010","journal-title":"Eur. J. health Econ. HEPAC health Econ. Prev. care"},{"key":"B46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1477-7525-6-113","article-title":"Evaluation of the reliability and validity of the Medical Outcomes Study sleep scale in patients with painful diabetic peripheral neuropathy during an international clinical trial","volume":"6","author":"Viala-Danten","year":"2008","journal-title":"Health Qual. life outcomes"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1483770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T04:05:05Z","timestamp":1738901105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1483770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":46,"alternative-id":["10.3389\/fphar.2025.1483770"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1483770","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"article-number":"1483770"}}